Sugi Predict

Sugi Predict / Compounds / SCHEMBL1521944

SCHEMBL1521944

SCHEMBL1521944

CN1C(=O)N(c2ccc(F)c(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ncccc4c3)c2)Cc2cnc(N)nc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 6/20 0.54
▸ MAPK14 Q16539 11/20 0.51
▸ SRC P12931 5/20 0.51
▸ MAPK11 Q15759 5/20 0.51
▸ EPHB4 P54760 3/20 0.51
▸ MAPK9 P45984 3/20 0.51
▸ DDR2 Q16832 3/20 0.51
▸ BRAF P15056 3/20 0.51
▸ AXL P30530 2/20 0.51
▸ PTK2 Q05397 2/20 0.51
▸ PTK2B Q14289 2/20 0.51
▸ LCK P06239 2/20 0.51
▸ FES P07332 2/20 0.51
▸ RET P07949 2/20 0.51
▸ KIT P10721 2/20 0.51
▸ FGFR1 P11362 2/20 0.51
▸ PDGFRA P16234 2/20 0.51
▸ FLT1 P17948 2/20 0.51
▸ FGFR3 P22607 2/20 0.51
▸ KDR P35968 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521814 0.90 MAPK14 (0.52) MAPK14SRCMAPK11MAPK9DDR2
SCHEMBL1521763 0.87 ABL1 (0.43) ABL1MAPK14SRCMAPK11EPHB4
SCHEMBL1521800 0.84 ABL1 (0.51) ABL1MAPK14SRCMAPK11EPHB4
SCHEMBL1521535 0.83 ABL1 (0.49) ABL1MAPK14SRCMAPK11EPHB4
SCHEMBL1521734 0.82 MAPK14 (0.51) MAPK14MAPK11DDR2BRAFFGFR4
SCHEMBL1521946 0.81 ABL1 (0.52) ABL1MAPK14SRCMAPK11EPHB4
SCHEMBL4429207 0.79 ABL1 (0.55) ABL1MAPK14SRCMAPK11EPHB4
SCHEMBL1521820 0.78 FGFR4 (0.43) ABL1MAPK14MAPK11BRAFBMX
SCHEMBL2079924 0.78 ABL1 (0.72) ABL1MAPK14SRCMAPK11EPHB4
SCHEMBL1521555 0.78 MAPK14 (0.53) MAPK14MAPK11BRAFPTK2MAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 — — US claimed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 — — US claimed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 — — US claimed
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 — — US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 — — US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 ABL1 936/4885MAPK14 240/4885SRC 417/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 ABL1 936/4885MAPK14 240/4885SRC 417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.